Prospective Randomized Blinded Placebo-Controlled Phase 2b Trial Of An Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells(DC) Vaccine Vs Unloaded YCWP + DC In Stage 3 And Stage IV (Resected) Melanoma To Prevent Recurrence

Brief description of study

If you have been diagnosed with melanoma and have received treatment for stage III or stage IV melanoma that has been surgically resected (removed) and you are at high risk for recurrence ( your melanoma coming back); you may qualify to participate in a study evaluating how effective a vaccine that is made from your tumor cells and white blood cells is at preventing your cancer from returning. The main purpose of this trial is to produce and test a vaccine that is made from your tumor cells and white blood cells to determine if it can prevent melanoma recurrence. This study will also evaluate the safety of the vaccine (what side effects it has) and the immune system’s response to this vaccine.


Clinical Study Identifier: s14-01915
ClinicalTrials.gov Identifier: NCT02301611
Principal Investigator: Anna C Pavlick
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.